Advinus Therapeutics, Ltd. and Merck have formed a drug discovery and clinical development collaboration in the area of metabolic disorders. The two companies will work together to develop clinically validated drug candidates for metabolic disorders, with Merck retaining the right to advance the most promising of these candidates into late-stage clinical trials. Advinus will receive an upfront payment and could potentially receive milestone payments of as much as $74.5 million for each tar...